-
Je něco špatně v tomto záznamu ?
Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis
AD. Lake, AL. Chaput, P. Novak, NJ. Cherrington, CL. Smith,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- down regulace MeSH
- lidé MeSH
- nealkoholová steatóza jater metabolismus MeSH
- progrese nemoci MeSH
- regulace genové exprese fyziologie MeSH
- stanovení celkové genové exprese MeSH
- transkripční faktory metabolismus MeSH
- upregulace MeSH
- vazba proteinů MeSH
- vazebná místa MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The molecular mechanisms behind the transition from simple steatosis to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) are not clearly understood. This hinders development of effective therapies for treatment and prevention of NASH. In this study expression profiling data from normal, steatosis, and NASH human livers were used to predict transcription factors that are misregulated as mechanistic features of NAFLD progression. Previously-published human NAFLD gene expression profiling data from normal, steatosis, and NASH livers were subjected to transcription factor binding site enrichment analysis. Selected transcription factors that bind enriched transcription factor binding sites were analyzed for changes in expression. Distinct transcription factor binding sites were enriched in genes significantly up- or down-regulated in NASH livers. Those enriched in up-regulated genes were bound by transcription factors such as FOXA, CEBP, and HNF1 family members, while those enriched in down-regulated genes were bound by nuclear receptors involved in xenobiotic sensing and lipid metabolism. Levels of mRNA and protein for selected transcription factors were significantly changed during disease progression. The study indicates that NAFLD progression involves changes in activity or expression of transcription factors that regulate genes involved in hepatic processes known to be altered in NASH. Transcription factors such as PPAR receptors, FoxA family members, and HNF4A might be targeted therapeutically to prevent NAFLD progression.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023508
- 003
- CZ-PrNML
- 005
- 20170720123533.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2016.11.006 $2 doi
- 035 __
- $a (PubMed)27836672
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lake, April D $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
- 245 10
- $a Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis / $c AD. Lake, AL. Chaput, P. Novak, NJ. Cherrington, CL. Smith,
- 520 9_
- $a The molecular mechanisms behind the transition from simple steatosis to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD) are not clearly understood. This hinders development of effective therapies for treatment and prevention of NASH. In this study expression profiling data from normal, steatosis, and NASH human livers were used to predict transcription factors that are misregulated as mechanistic features of NAFLD progression. Previously-published human NAFLD gene expression profiling data from normal, steatosis, and NASH livers were subjected to transcription factor binding site enrichment analysis. Selected transcription factors that bind enriched transcription factor binding sites were analyzed for changes in expression. Distinct transcription factor binding sites were enriched in genes significantly up- or down-regulated in NASH livers. Those enriched in up-regulated genes were bound by transcription factors such as FOXA, CEBP, and HNF1 family members, while those enriched in down-regulated genes were bound by nuclear receptors involved in xenobiotic sensing and lipid metabolism. Levels of mRNA and protein for selected transcription factors were significantly changed during disease progression. The study indicates that NAFLD progression involves changes in activity or expression of transcription factors that regulate genes involved in hepatic processes known to be altered in NASH. Transcription factors such as PPAR receptors, FoxA family members, and HNF4A might be targeted therapeutically to prevent NAFLD progression.
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a down regulace $7 D015536
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a regulace genové exprese $x fyziologie $7 D005786
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nealkoholová steatóza jater $x metabolismus $7 D065626
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a transkripční faktory $x metabolismus $7 D014157
- 650 _2
- $a upregulace $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chaput, Alexandria L $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
- 700 1_
- $a Novak, Petr $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States; Biology Centre ASCR, Institute of Plant Molecular Biology, Branisovska 31, Ceske Budejovice CZ-37005, Czech Republic.
- 700 1_
- $a Cherrington, Nathan J $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States.
- 700 1_
- $a Smith, Catharine L $u Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, United States. Electronic address: csmith@pharmacy.arizona.edu.
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 122, č. - (2016), s. 62-71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27836672 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170720124026 $b ABA008
- 999 __
- $a ok $b bmc $g 1239189 $s 984421
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 122 $c - $d 62-71 $e 20161109 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20170720